Cargando…

Prognostic studies in patients with high-risk primary breast cancer (HRPBC) receiving high-dose chemotherapy (HDC)

Detalles Bibliográficos
Autor principal: Nieto, Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231906/
http://dx.doi.org/10.1186/bcr1226
_version_ 1782344496447488000
author Nieto, Y
author_facet Nieto, Y
author_sort Nieto, Y
collection PubMed
description
format Online
Article
Text
id pubmed-4231906
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42319062014-11-17 Prognostic studies in patients with high-risk primary breast cancer (HRPBC) receiving high-dose chemotherapy (HDC) Nieto, Y Breast Cancer Res Oral Presentation BioMed Central 2005 2005-05-27 /pmc/articles/PMC4231906/ http://dx.doi.org/10.1186/bcr1226 Text en
spellingShingle Oral Presentation
Nieto, Y
Prognostic studies in patients with high-risk primary breast cancer (HRPBC) receiving high-dose chemotherapy (HDC)
title Prognostic studies in patients with high-risk primary breast cancer (HRPBC) receiving high-dose chemotherapy (HDC)
title_full Prognostic studies in patients with high-risk primary breast cancer (HRPBC) receiving high-dose chemotherapy (HDC)
title_fullStr Prognostic studies in patients with high-risk primary breast cancer (HRPBC) receiving high-dose chemotherapy (HDC)
title_full_unstemmed Prognostic studies in patients with high-risk primary breast cancer (HRPBC) receiving high-dose chemotherapy (HDC)
title_short Prognostic studies in patients with high-risk primary breast cancer (HRPBC) receiving high-dose chemotherapy (HDC)
title_sort prognostic studies in patients with high-risk primary breast cancer (hrpbc) receiving high-dose chemotherapy (hdc)
topic Oral Presentation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231906/
http://dx.doi.org/10.1186/bcr1226
work_keys_str_mv AT nietoy prognosticstudiesinpatientswithhighriskprimarybreastcancerhrpbcreceivinghighdosechemotherapyhdc